Document Detail


The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
MedLine Citation:
PMID:  20859106     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with schizophrenia have a greater incidence of being overweight or obese compared with the general population. Such individuals are often treated with second-generation (atypical) antipsychotics (SGAs), which are associated with weight gain, dyslipidemia, and other metabolic derangements. As a result, frequent monitoring of weight and other metabolic parameters is recommended. In addition, several pharmacologic strategies to help prevent or reduce SGA-induced weight gain have been proposed. Despite this, clinicians often struggle to manage obesity and metabolic issues in such patients. Metformin has attracted attention as a potential treatment option because it is thought to result in weight reduction and improved glycemic control in obese patients with and without type 2 diabetes mellitus. This article focuses on relevant pharmacologic aspects of metformin and reviews currently available evidence on the use of metformin as an augmentation agent for the treatment or prevention of SGA-induced weight gain.
Authors:
Ahsan Y Khan; Matthew Macaluso; Robert J McHale; Megan M Dahmen; Kathrine Girrens; Faryal Ali
Related Documents :
16305056 - Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein...
16492206 - Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients...
17686386 - Effects of thiazolidinediones on blood pressure.
18158076 - Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue,...
16188896 - Angiotensin ii sensitivity of afferent glomerular arterioles in endothelin-1 transgenic...
6591766 - Influence of autonomic neuropathy on leg circulation and toe temperature in diabetes me...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of psychiatric practice     Volume:  16     ISSN:  1538-1145     ISO Abbreviation:  J Psychiatr Pract     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-22     Completed Date:  2011-02-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100901141     Medline TA:  J Psychiatr Pract     Country:  United States    
Other Details:
Languages:  eng     Pagination:  289-96     Citation Subset:  IM    
Affiliation:
University of Kansas School of Medicine-Wichita †Via Christi Regional Medical Center, Wichita, KS 67214, USA. akhan@kumc.edu
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00816907
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antipsychotic Agents / administration & dosage,  adverse effects*
Blood Glucose / drug effects
Body Weight / drug effects
Humans
Hypoglycemic Agents / therapeutic use*
Metformin / therapeutic use*
Obesity / chemically induced,  drug therapy
Overweight / chemically induced*,  drug therapy*
Schizophrenia / drug therapy*
Treatment Outcome
Weight Loss / drug effects
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Blood Glucose; 0/Hypoglycemic Agents; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Countering side effects.
Next Document:  Improving marital quality in women with medical illness: integration of evidence-based programs into...